Bioactive toothpastes in dentin hypersensitivity treatment: A systematic review.

Autor:	Freitas SAA; School of Dentistry, Federal University of Maranhão (UFMA), São Luís, Maranhão, Brazil., Oliveira NMA; School of Dentistry, Federal University of Maranhão (UFMA), São Luís, Maranhão, Brazil., de Geus JL; School of Dentistry, Paulo Picanço Faculty, Fortaleza, Ceará, Brazil., Souza SFC; School of Dentistry, Federal University of Maranhão (UFMA), São Luís, Maranhão, Brazil., Pereira AFV; School of Dentistry, Federal University of Maranhão (UFMA), São Luís, Maranhão, Brazil., Bauer J; School of Dentistry, Federal University of Maranhão (UFMA), São Luís, Maranhão, Brazil.
Jazyk:	angličtina
Zdroj:	The Saudi dental journal [Saudi Dent J] 2021 Nov; Vol. 33 (7), pp. 395-403. Date of Electronic Publication: 2021 Apr 27.
DOI:	10.1016/j.sdentj.2021.04.004
Abstrakt:	The use of bioactive materials is a recent proposal in the treatment of dentin hypersensitivity (DH) due to the ability to stimulate the neoformation of a barrier on dentin surface. Questions have arisen about the effectiveness of the materials to reduce DH when compared to the control groups (placebo or non-bioactive substance). Thus, the aim of this systematic review was to evaluate the randomized controlled trials in adult patients for DH treatment with a dentifrice containing bioactive glass, applied either at-home or in-office. Methods : The study was registered in PROSPERO and followed PRISMA guidelines. Searches were carried out in four databases (Pubmed/Medline, CENTRAL, Wbb of Science, LILACS) spanning from February 2020 to March 2020, with no language or publication date restrictions. A supplementary hand-search was performed by checking the list of references. The so-called gray literature of the national and international databases for theses and dissertations, as well as unfinished, in progress and unpublished studies were also searched. Results : After reading the titles and abstracts, articles that were duplicated (74 records) or unrelated to the systematic review (76 records) were excluded. Fifteen studies were evaluated considering seven at low risk of bias, four at high risk and four at moderate risk. Conclusion: The bioactive compounds at low concentrations (2.5-7.5%) can be used as treatment of DH both at-home and in-office. Competing Interests: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. (© 2021 The Authors.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu